Uzi Sofer - Alpha Tau CEO Chairman
| DRTS Stock | USD 2.32 0.02 0.87% |
Insider
Uzi Sofer is CEO Chairman of Alpha Tau Medical
| Age | 54 |
| Address | Kiryat Hamada Street 5, Jerusalem, Israel, 9777605 |
| Phone | 972 3 577 4115 |
| Web | https://www.alphatau.com |
Alpha Tau Management Efficiency
The company has return on total asset (ROA) of (0.2192) % which means that it has lost $0.2192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3317) %, meaning that it created substantial loss on money invested by shareholders. Alpha Tau's management efficiency ratios could be used to measure how well Alpha Tau manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.37 in 2024, whereas Return On Tangible Assets are likely to drop (0.29) in 2024. At this time, Alpha Tau's Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 669.9 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 11.5 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pr Staels | Genfit | 61 | |
| Thomas Baetz | Genfit | 49 | |
| Bren Kern | Eyenovia | 43 | |
| MA MS | Inozyme Pharma | N/A | |
| MSc MBA | Inozyme Pharma | 52 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Pascal Prigent | Genfit | 55 | |
| Maria Mancini | Champions Oncology | N/A | |
| MS MBA | Inozyme Pharma | 47 | |
| Saptarsi MD | Tenaya Therapeutics | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Sheng Ding | Tenaya Therapeutics | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Alexander Lobo | Eyenovia | N/A | |
| Deepak MD | Tenaya Therapeutics | 58 | |
| Hing Wong | HCW Biologics | 70 | |
| Philip Strassburger | Ocular Therapeutix | 64 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Stefanie Magner | Genfit | 43 | |
Management Performance
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.22 |
Alpha Tau Medical Leadership Team
Elected by the shareholders, the Alpha Tau's board of directors comprises two types of representatives: Alpha Tau inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpha. The board's role is to monitor Alpha Tau's management team and ensure that shareholders' interests are well served. Alpha Tau's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpha Tau's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Chief Board | ||
| Rebecca Becker, Vice legal | ||
| Pr Kelson, Chief Board | ||
| Yael Zeiger, Corporate Controller | ||
| Raphi Levy, Chief Officer | ||
| Peter Melnyk, Chief Officer | ||
| Pr Keisari, Chief board | ||
| Ronen Segal, Chief Officer | ||
| Uzi Sofer, CEO Chairman | ||
| Amnon Gat, Chief Officer |
Alpha Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpha Tau a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 108.23 M | ||||
| Shares Outstanding | 70.1 M | ||||
| Shares Owned By Insiders | 25.56 % | ||||
| Shares Owned By Institutions | 1.94 % | ||||
| Number Of Shares Shorted | 67.06 K | ||||
| Price To Book | 2.32 X | ||||
| EBITDA | (28.03 M) | ||||
| Net Income | (29.16 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alpha Stock Analysis
When running Alpha Tau's price analysis, check to measure Alpha Tau's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alpha Tau is operating at the current time. Most of Alpha Tau's value examination focuses on studying past and present price action to predict the probability of Alpha Tau's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alpha Tau's price. Additionally, you may evaluate how the addition of Alpha Tau to your portfolios can decrease your overall portfolio volatility.